Mednet Logo

How do you best incorporate use of filgrastim/pegfilgrastim in capecitabine based regimens?

3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center
Answered on

Neutropenia during capecitabine is almost always a dose-related issue. Neutropenia can be thought of as a pharmacodynamic marker of drug exposure. If a patient is experiencing dose-limiting neutropenia during capecitabine-based therapy, they are likely receiving an excessive dose of one of the chemo...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Wisconsin
Answered on

Since you can’t use G-CSF or similar agents while on chemo, the long duration of capecitabine regimens such as cape/ox functionally prohibits its use. Instead, I would favor dose reduction as the best strategy to improve neutropenia.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on

Capecitabine is a novel fluoropyrimidine carbamate, a prodrug of 5-fluorouracil, that is rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue. After oral intake, capecitabine is converted to 5-fluorouracil through a 3-step enzymatic process. It is first metabolized in...

Join for free or sign in to see the full answer